Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 23Sarcoma 3Thoracic 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 183Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Hematologic Neoplasms 91Leukemia, Lymphocytic, Chronic, B-Cell 88Myelodysplastic Syndromes 70Leukemia 59Lymphoma 44Multiple Myeloma 40Lymphoma, Non-Hodgkin 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Burkitt Lymphoma 27Recurrence 23Neoplasms 22Leukemia, Myelomonocytic, Chronic 21Myeloproliferative Disorders 20Hodgkin Disease 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Large B-Cell, Diffuse 19Leukemia, Biphenotypic, Acute 18Lymphoma, Mantle-Cell 17Leukemia, B-Cell 16Lymphoma, B-Cell 15Lymphoma, Follicular 14Waldenstrom Macroglobulinemia 13Anemia, Refractory, with Excess of Blasts 13Myelodysplastic-Myeloproliferative Diseases 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Hairy Cell 9Blast Crisis 9Primary Myelofibrosis 8

Interventions

trametinib 1omipalisib 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Other hematologic neoplasm × 30 days × Clear all
NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 11 charts
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡